Paper Details

  1. Home
  2. Paper Details

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.

Author: ColleoniM, GraiffC, ManenteP, NelliP, PancheriF, SgarbossaG, VicarioG

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the activity of a combination therapy of estramustine, etoposide, and vinorelbine in patients with hormone-refractory prostate cancer. The treatment showed a 32% response rate, with a median duration of response of 3 months. The toxicity was manageable.
Paper Details　
Original Abstract of the Article :
Hormone-refractory prostate cancer is characterized by a low response rate following second-line therapy. Encouraging results have been reported in Phase II studies with estramustine associated with vinblastine or etoposide. Vinorelbine is a new semisynthetic vinca alkaloid that has demonstrated act...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00000421-199708000-00013

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of Hormone-Refractory Prostate Cancer

Navigating the harsh landscape of hormone-refractory prostate cancer, we are constantly searching for treatments that can offer relief and hope. This Phase II study explores a new combination therapy of estramustine, oral etoposide, and vinorelbine. Like a skilled caravan leader combining different resources to ensure a successful journey, researchers tested this regimen on 25 patients with hormone-refractory prostate cancer, analyzing its effectiveness and side effects.

The Promise of a New Route: A 32% Response Rate

The study yielded encouraging results, showing an overall response rate of 32%, with two patients with measurable disease and six patients with bone disease achieving partial remission. The median duration of response was 3 months. These findings are like discovering a hidden spring in the desert, offering a flicker of hope in a challenging situation. The combination therapy was also well-tolerated, with manageable side effects.

Navigating the Terrain: A Well-Tolerated Option

The study highlights the potential benefits of this new combination therapy for patients with hormone-refractory prostate cancer. The manageable side effects and encouraging response rate make it a promising option for these patients. It is important to note that this was a Phase II study, and further research is needed to confirm these findings and understand the long-term effects of this treatment. However, the results offer a ray of hope in the fight against this challenging disease.

Dr. Camel's Conclusion

This study presents a promising new approach to treating hormone-refractory prostate cancer. While further research is needed to confirm its effectiveness, the results offer hope for patients facing this challenging disease. The manageable side effects and encouraging response rate make it a potential oasis in the vast desert of treatment options.

Date :
  1. Date Completed 1997-09-04
  2. Date Revised 2019-09-05
Further Info :

Pubmed ID

9256895

DOI: Digital Object Identifier

10.1097/00000421-199708000-00013

Related Literature

Article Analysis
・Side Effects of estramustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.